Eli Lilly and Company Stock News

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. The company faced criticism for high prices, supply blockages and the rise of counterfeits. It has now addressed all these concerns. Zepbound's price cuts can make at least some customers happy, its latest packaging allows for bigger supplies, and the online portal can reduce t...

Eli Lilly and Egypt's EVA Pharma have entered into an agreement to license Lilly's rheumatoid arthritis drug in 49 countries in Africa, the companies said on Wednesday.

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa INDIANAPOLIS and CAIRO , Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and  EVA Pharma  announced today that the companies have entered into an agreement to expand access to...

Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.

BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States.

While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

Market values of major tech firms declined in August amid concerns over escalating artificial intelligence infrastructure costs and rising recession risks that would make the stocks particularly vulnerable during a market correction.